Phase II study of Exemestane dose intensification (150 mg daily) in postmenopausal patients with advanced breast cancer progressing under standard dose Exe (25 mg daily) given as adjuvant or palliative therapy.
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2013
At a glance
- Drugs Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Jul 2011 New trial record